Is TALPHERA, INC. (TLPH) Halal?

NASDAQ Healthcare United States $37M
✓ HALAL
Confidence: 67/100
TALPHERA, INC. (TLPH) is Halal under 3 of 5 Shariah screening standards, including AAOIFI Standard 21. With a debt ratio of just 0.0% against the AAOIFI threshold of 30%, TALPHERA, INC. comfortably passes the key financial ratio tests. The company operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic), which is not a prohibited industry under Islamic finance principles.

Shariah Screening — 5 Standards

Based on financial data from December 2024

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 0.0%
/ 30%
21.9%
/ 30%
0.0%
/ 30%
N/A ✓ HALAL
DJIM 0.0%
/ 33%
21.9%
/ 33%
0.0%
/ 33%
N/A ✓ HALAL
MSCI 0.0%
/ 33%
48.6%
/ 33%
0.0%
/ 33%
N/A ✗ NOT HALAL
S&P 0.0%
/ 33%
21.9%
/ 33%
0.0%
/ 33%
N/A ✓ HALAL
FTSE 0.0%
/ 33%
48.6%
/ 33%
0.0%
/ 50%
N/A ✗ NOT HALAL

Financial Highlights

EPS
$-0.34
P/B Ratio
2.1
Revenue
$0
Beta
0.5
Low volatility
Current Ratio
5.5

Profitability

Gross Margin 0.0%
Operating Margin -48157.1%
Net Margin 0.0%
Return on Equity (ROE) -114.7%
Return on Assets (ROA) -35.1%

Cash Flow & Balance Sheet

Operating Cash Flow-$13M
Free Cash Flow-$13M
Debt-to-Equity38.2
Current Ratio5.5
Total Assets$18M

Price & Trading

Last Close$0.77
50-Day MA$0.87
200-Day MA$0.87
Avg Volume252K
Beta0.5
52-Week Range
$0.38
$1.57

About TALPHERA, INC. (TLPH)

CEO
Mr. Vincent J. Angotti
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
United States
Exchange
NASDAQ
Market Cap
$37M
Currency
USD

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, a nafamostat formulation for direct IV infusion as an investigational product for various indications, such as antiviral, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis, as well as Fedsyra and phenylephrine ready-to-use pre-filled syringe product candidates. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is based in San Mateo, California.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is TALPHERA, INC. (TLPH) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), TALPHERA, INC. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is TALPHERA, INC.'s debt ratio?

TALPHERA, INC.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.

What are TALPHERA, INC.'s key financial metrics?

TALPHERA, INC. has a market capitalization of $37M. Return on equity stands at -114.7%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.